Korro Bio (KRRO) Amortizatization of Intangibles (2023 - 2026)
Korro Bio's (KRRO) quarterly Amortizatization of Intangibles came in at -$2000.0 in Q1 2026, down 100.59% YoY from $340000.0 in Q1 2025, and down 109.09% on a QoQ basis from $22000.0 in Q4 2025.
Korro Bio (KRRO) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends
Korro Bio (KRRO) has 4 years of Amortizatization of Intangibles data on file, last reported at -$2000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 100.59% year-over-year to -$2000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $147000.0 (down 93.07% YoY) and the FY2025 annual result came in at $489000.0, down 72.56% from the prior year.
- Amortizatization of Intangibles eased to -$2000.0 in Q1 2026, from $22000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $988000.0 in Q3 2024 to a low of -$2000.0 in Q1 2026.
- A 4-year average of $213545.5 and a median of $68000.0 in 2023 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2024 — Amortizatization of Intangibles soared 98700.0% — and 2026, when it plunged 100.59%.
- Tracing KRRO's Amortizatization of Intangibles over 4 years: stood at $1000.0 in 2023, then soared by 62200.0% to $623000.0 in 2024, then slumped by 96.47% to $22000.0 in 2025, then plunged by 109.09% to -$2000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at -$2000.0 (Q1 2026), $22000.0 (Q4 2025), and $47000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Korro Bio | 231.77 Mn | 116.73 Mn | - | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,000.00 |
| Jun 30, 2026 | -1,000.00 |
| Mar 31, 2026 | -2,000.00 |
| Mar 31, 2026 | -2,000.00 |
| Dec 31, 2025 | 22,000.00 |
| Dec 31, 2025 | 22,000.00 |
| Sep 30, 2025 | 47,000.00 |
| Sep 30, 2025 | 47,000.00 |
| Jun 30, 2025 | 80,000.00 |
| Jun 30, 2025 | 80,000.00 |
| Mar 31, 2025 | 340,000.00 |
| Mar 31, 2025 | 340,000.00 |
| Dec 31, 2024 | 623,000.00 |
| Dec 31, 2024 | 623,000.00 |
| Sep 30, 2024 | 988,000.00 |
| Sep 30, 2024 | 988,000.00 |
| Jun 30, 2024 | 171,000.00 |
| Jun 30, 2024 | 171,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Sep 30, 2023 | 1,000.00 |